Study Protocol: Phase II dose-response pilot study of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in subjects with anxiety associated with advanced-stage cancer.
Principal Investigator: John H. Halpern, M.D.	Sponsor: Multidisciplinary Association for Psychedelic Studies (MAPS)